Who is sponsoring NCT01146002?

NCT01146002 is sponsored by Neurology Group of Bergen County, P.A..

What drugs are being tested in NCT01146002?

Interventions in NCT01146002: Guanfacine (sustained release).

What condition does NCT01146002 study?

NCT01146002 studies Attention-deficit/Hyperactivity Disorder.

Is NCT01146002 still recruiting?

NCT01146002 is currently completed. Last updated 1 April 2014.

Last reviewed 2014-04-01 · How we verify

NCT01146002

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine

Completed Phase 4 Last updated 1 April 2014

What this trial tests

Phase 4 trial testing Guanfacine (sustained release) in Attention-deficit/Hyperactivity Disorder in 30 participants. Completed in 1 February 2013.

Timeline

1 June 2010

Primary endpoint
1 February 2013

1 February 2013

Quick facts

Lead sponsor	Neurology Group of Bergen County, P.A.
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 June 2010
Primary completion	1 February 2013
Estimated completion	1 February 2013
Sites	1 location across United States

Drugs / interventions tested

Guanfacine (sustained release) — full drug profile →

Conditions studied

Attention-deficit/Hyperactivity Disorder — all drugs for Attention-deficit/Hyperactivity Disorder →

Sponsor

Neurology Group of Bergen County, P.A. — full company profile →

Who can join

Adults 6 to 12, any sex, with Attention-deficit/Hyperactivity Disorder. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

one-tailed t-test
Time frame: 7 weeks
Improvement in Woodcock Johnson III score when taking sustained release guanfacine, compared to score on the same test prior to treatment.

Sponsor's own description

This study is investigating the effect of sustained-release guanfacine (Intuniv) on language-based learning skills in children age 6-12 who are diagnosed with attention deficit hyperactivity disorder (ADHD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Attention-deficit/Hyperactivity Disorder

Currently open trials in the same condition.

NCT06743425 — A Pilot Study of a Remote ADHD Monitoring Program · NA · recruiting
NCT06376331 — Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01146002 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neurology Group of Bergen County, P.A.
Last refreshed: 1 April 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01146002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing